Lamellar Biomedical said today that the 1st patients were enrolled in its trial evaluating Lamelleye for the treatment of moderate to severe dry-eye disease.
Lamelleye uses the Scotland-based company’s Lamellasome technology to mimic the actions of serous lamellar bodies and regulate interfaces between tissues and external environments.
Get the full story at our sister site, Drug Delivery Business News.
The post Lamellar Biomedical launches dry-eye trial appeared first on MassDevice.
from MassDevice http://ift.tt/2rEi7BT
Cap comentari:
Publica un comentari a l'entrada